» Articles » PMID: 29847332

Predictors of Chronic Kidney Disease and Utility of Risk Prediction Scores in HIV-positive Individuals

Overview
Journal AIDS
Date 2018 May 31
PMID 29847332
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The current study aimed to validate existing risk prediction scores and identify predictors of chronic kidney disease (CKD) in the setting of HIV.

Design And Methods: A retrospective cohort study of HIV-positive individuals (n = 748) with baseline estimated glomerular filtration rate (eGFR) more than 60 ml/min was conducted at the Alfred Hospital, Melbourne, Australia. Multivariable regression analysis was performed to determine factors associated with development of CKD, defined as two consecutive measurements of eGFR less than 60 ml/min. The performance of CKD risk scores proposed by the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group and Scherzer and colleagues were estimated by the area under the receiver operator curve (AUROC).

Results: CKD developed in 37 individuals (5.0%), at a median of 4.7 (interquartile range 2.2, 6.2) years. Older age [odds ratio (OR) 3.03, 95% confidence interval (CI): 1.20, 7.65, P = 0.02] and lower baseline eGFR (OR 10.39, 95% CI: 4.73, 22.83, P < 0.001) were associated with the development of CKD. Neither current, nor cumulative tenofovir disoproxil fumarate (TDF) use was associated with progression to CKD [current TDF hazard ratio (HR) 1.05, 95% CI: 0.54, 2.07, P = 0.88; cumulative TDF HR 1.03, 95% CI: 0.86, 1.24, P = 0.75]. The short D:A:D and Scherzer scores were well calibrated, with the short D:A:D score demonstrating superior discrimination (short D:A:D AUROC 0.85, Scherzer AUROC 0.78, P = 0.02).

Conclusion: Older individuals and those with a lower baseline eGFR are at higher risk for CKD. Risk prediction tools may be useful in identifying those at greatest risk, who may benefit from aggressive management of risk factors.

Citing Articles

Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.

Yazie T, Shiferaw W, Gebeyehu A, Teshome A, Addisu Z, Belete A PLoS One. 2025; 20(2):e0318068.

PMID: 39913460 PMC: 11801554. DOI: 10.1371/journal.pone.0318068.


Renal outcomes in adults with HBV, HIV and HBV/HIV coinfection after 3 years of antiviral therapy in urban Tanzania.

Wu E, Christian B, Rivera A, Fabian E, Macha I, Aris E J Antimicrob Chemother. 2023; 79(1):36-45.

PMID: 37935111 PMC: 11491651. DOI: 10.1093/jac/dkad341.


Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis.

Shi R, Chen X, Lin H, Ding Y, He N BMC Nephrol. 2022; 23(1):107.

PMID: 35300612 PMC: 8932163. DOI: 10.1186/s12882-022-02721-x.


Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration.

Poda A, Kabore N, Malateste K, de Rekeneire N, Semde A, Bikinga Y HIV Med. 2020; 22(2):113-121.

PMID: 33145918 PMC: 8593822. DOI: 10.1111/hiv.12982.


Validation of the D: A: D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific.

Han W, Bijker R, Chandrasekaran E, Pujari S, Ng O, Ly P J Acquir Immune Defic Syndr. 2020; 85(4):489-497.

PMID: 33136750 PMC: 8018533. DOI: 10.1097/QAI.0000000000002464.